Yi He

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Peter A. Kaufman, Ahmad Awada, Chris Twelves et al. · Journal of Clinical Oncology · 2015 · 464 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

Chris Twelves, Javier Cortés, Linda T. Vahdat et al. · Breast Cancer Research and Treatment · 2014 · 216 citations · Full text

Medicine, Oncology, Pharmacology +12

ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.

David A. Reardon, James M. Schuster, David Tran et al. · Journal of Clinical Oncology · 2015 · 75 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson et al. · Cancer · 2019 · 75 citations · Full text

Medicine, Oncology, Pharmacotherapy +17